| Balance Sheets | 2025-09-30 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 139,376 | |||
| Short-term investments | 525,146 | |||
| Accounts receivable, net | 57,560 | |||
| Inventory | 11,900 | |||
| Short-term portion of financial royalty assets, net | 12,416 | |||
| Income taxes receivable | 536 | |||
| Other current assets | 6,986 | |||
| Total current assets | 753,920 | |||
| Intangible assets, net | 233,535 | |||
| Goodwill | 101,541 | |||
| Long-term portion of financial royalty assets, net | 206,332 | |||
| Noncurrent derivative assets | 9,351 | |||
| Property and equipment, net | 3,466 | |||
| Lease right-of-use assets | 7,609 | |||
| Equity method investments | 42,000 | |||
| Other investments | 106,721 | |||
| Deferred income taxes, net | 9,526 | |||
| Other assets | 2,771 | |||
| Total assets | 1,476,772 | |||
| Accounts payable | 3,679 | |||
| Accrued liabilities | 24,084 | |||
| Income taxes payable | 1,284 | |||
| Current contingent liabilities | 268 | |||
| Current operating lease liabilities | 1,089 | |||
| Other current liabilities | 135 | |||
| Total current liabilities | 30,539 | |||
| Long-term deferred revenue | 0 | |||
| Long-term contingent liabilities | 3,569 | |||
| Long-term operating lease liabilities | 4,415 | |||
| Long-term portion of 2030 convertible senior notes, net | 445,493 | |||
| Deferred income taxes, net | 22,673 | |||
| Other long-term liabilities | 19,912 | |||
| Total liabilities | 526,601 | |||
| Common stock, 0.001 par value 60,000 shares authorized 19,656 and 19,106 shares issued and outstanding at september30, 2025 and december31, 2024, respectively | 20 | |||
| Additional paid-in capital | 362,614 | |||
| Accumulated other comprehensive income (loss) | 9,322 | |||
| Retained earnings | 578,215 | |||
| Total stockholders equity | 950,171 | |||
| Total liabilities and stockholders equity | 1,476,772 | |||
LIGAND PHARMACEUTICALS INC (LGNZZ)
LIGAND PHARMACEUTICALS INC (LGNZZ)